Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
NCT07531095
This study is recruiting at 7 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
The primary objective of this trial is to evaluate the safety and tolerability of tarlatamab in combination with ZL-1310 with or without durvalumab and to determine the maximum tolerated combination dose (MTCD) and/or recommended phase 2 dose (RP2D) of ZL-1310 in combination with tarlatamab.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Small Cell Lung Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Amgen
- Last updated on ClinicalTrials.gov
- August 21, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- City of Hope Cancer Center Phoenix · Goodyear, AZ
Florida · 1
- Moffitt Cancer Center · Tampa, FL
Illinois · 1
- City of Hope Chicago · Zion, IL
Minnesota · 1
- Health Partners Cancer Center at Regions Hospital · Saint Paul, MN
New York · 1
- New York University Cancer Institute · New York, NY
Tennessee · 1
- Baptist Cancer Center · Memphis, TN
Virginia · 1
- Next Virginia · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.